[go: up one dir, main page]

US4323581A - Method of treating carcinogenesis - Google Patents

Method of treating carcinogenesis Download PDF

Info

Publication number
US4323581A
US4323581A US05/929,094 US92909478A US4323581A US 4323581 A US4323581 A US 4323581A US 92909478 A US92909478 A US 92909478A US 4323581 A US4323581 A US 4323581A
Authority
US
United States
Prior art keywords
retinamide
hydroxyphenyl
mnu
diet
carcinogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/929,094
Inventor
Robert J. Gander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson
Original Assignee
Johnson and Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson and Johnson filed Critical Johnson and Johnson
Priority to US05/929,094 priority Critical patent/US4323581A/en
Priority to ZA786950A priority patent/ZA786950B/en
Priority to CA000329784A priority patent/CA1142092A/en
Assigned to JOHNSON & JOHNSON, A CORP. OF NJ. reassignment JOHNSON & JOHNSON, A CORP. OF NJ. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: GANDER, ROBERT J.
Application granted granted Critical
Publication of US4323581A publication Critical patent/US4323581A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Definitions

  • This invention relates to the use of chemicals to prevent the development of cancer in mammals. More particularly, it relates to the use of a retinoid, N-(4-hydroxyphenyl)-all-trans-retinamide, to prevent certain forms of epithelial cancer.
  • an alternative approach to the problem of epithelial cancer is to consider the disease as a process which takes many years to reach its final, invasive stage in man and which might be controlled by physiological or pharmacological mechanisms during its early stages, with the goal of prevention of end-stage, invasive, terminal disease.
  • Retinoids play an essential role in controlling the normal differentiation of epithelial tissues and are therefore important for controlling premalignant epithelial cell differentiation. It has even been found that retinoids can cause cellular repair of hyperplastic and anaplastic lesions caused by chemical carcinogens. Moreover, retinoid deficiency has been shown, in experimental animals, to enhance susceptibility to chemical carcinogenesis. Indeed, retinoids are essential for the normal cellular differentiation of epithelia that account for more than half of the total primary cancer in both men and women. These epithelia include those of the bronchi and trachea, stomach, intestine, uterus, kidney and bladder, testis, prostate, pancreatic ducts, and skin. In the absence of retinoids in the diet, normal cellular differentiation does not occur in these epithelia.
  • N-(4-hydroxyphenyl)-all-trans-retinamide is disclosed as being a good ultraviolet absorber that does not have the irritating effect on skin that would be expected from the use of sunscreening amounts of retinoic acid.
  • This compound is claimed in a divisional of the above-identified application, U.S. patent application Ser. No. 906,168, filed May 15, 1978.
  • a solution of retinoyl chloride was prepared by magnetically stirring 3.00 g. of all-trans-retinoic acid and 0.92 g. of phosphorous trichloride for 2.25 hours in 50 ml. of dry benzene. During 21 minutes, the retinoyl chloride solution was then added to a solution of 5.46 g. of 4-aminophenol in 16 ml. of anhydrous N,N-dimethylformamide and 2 ml. of anhydrous ethyl ether, while stirring under a nitrogen atmosphere and cooling in an ice bath. Stirring was then continued for three hours at room temperature and for an hour more at 50° C.
  • the reaction mixture was diluted with 150 ml. of ethyl ether.
  • the ether solution was extracted with two 25-ml. portions of cold 5% hydrochloric acid and then was washed with four 25-ml. portions of cold water. After the washed solution was dried over sodium sulfate, the solvent was evaporated, leaving a dark-yellow solid.
  • the solid was recrystallized first from methanol (6 ml. per gram), then from 1:1.7 chloroform-n-hexane (8 ml. per gram).
  • the product had a melting point of 159°-160° C.
  • the proton magnetic resonance spectrum of the product was consistent with the structure with no extraneous resonances.
  • the N-(4-hydroxyphenyl)-all-trans-retinamide is administered systemically, preferably orally, in a pharmaceutically acceptable vehicle compatible therewith at a dosage level effective to prevent or retard carcinogenesis but below that which would be toxic.
  • the drug is administered at regular intervals, conveniently at meal times or once daily. It has been established that the LD 50 of the active compound (in Swiss mice) is 436 mg/kg when given interperitoneally and in excess of 400 mg/kg when given orally. On the other hand, oral doses of 32 and 64 mg/kg/day have been found to be very effective in preventing breast cancer in rats. It is believed that for other mammals, a suitable effective dosage level will be within the above range and, probably, lower doses will also prove useful.
  • N-(4-hydroxyphenyl)-all-trans-retinamide was compared with retinoic acid in an in vitro screening model for identifying retinoids having activity in preventing carcinogenesis in epithelial tissue.
  • the experimental method which is described in Experimental Lung Cancer:Intern'l Symp, 575-82, 1974, involves reversal of keratinization in tracheal organ culture.
  • test organ culture of tracheal epithelium undergoes abnormal differentiation.
  • Addition of small concentrations of retinoic acid (as low as 10 -9 M) will cause reversion to normal tracheal epithelium.
  • Test compounds are compared in activity to retinoic acid or another active standard both as regards squamous metaplasia and keratin production, both of which are measures of abnormal development of the epithelial culture.
  • N-(4-hydroxyphenyl)-all-trans-retinamide was compared to retinyl acetate in the experimental assay for efficacy against rat breast cancer described in Nature Vol. 267, pp 620-621 (June 16, 1977), which measures the ability to inhibit mammary carcinogenesis induced by N-methyl-N-nitrosourea (MNU).
  • MNU N-methyl-N-nitrosourea
  • Table II The results of further extension of the tests, comparing the 4-hydroxyphenyl retinamide only to placebo, after 18 weeks with high dose MNU and 21 weeks with low dose MNU, are set forth in Table III.
  • the results using these two different levels of MNU and two dietary levels of retinoid are shown graphically in FIGS. 1 and 2 after 18 weeks of testing.
  • the 4-hydroxyphenyl retinamide substantially as efficacious as retinyl acetate, it is also less toxic.
  • this retinamide does not accumulate in the liver in appreciable amounts, thus avoiding the hepatotoxicity associated with prolonged use of the natural esters.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Periodic administration of N-(4-hydroxyphenyl)-all-trans-retinamide has been found to prevent breast cancer in mammals.

Description

TECHNICAL FIELD
This invention relates to the use of chemicals to prevent the development of cancer in mammals. More particularly, it relates to the use of a retinoid, N-(4-hydroxyphenyl)-all-trans-retinamide, to prevent certain forms of epithelial cancer.
BACKGROUND ART
As pointed out in a paper entitled "Approaches to Prevention of Epithelial Cancer During The Preneoplastic Period", Cancer Research, 36 (July, 1976), 2699-2702, presented at a Conference on "Early Lesions and The Development of Epithelial Cancer" (National Cancer Institute, Oct. 21-23, 1975), the death rates for several common forms of epithelial cancer either increased or showed no decrease during the 20-year period from 1950 to 1970. These epithelial cancer sites included the lung and pancreas in both men and women, the colon and bladder in men, the breast and ovary in women. The conventional clinical approach that has been followed with most epithelial cancer has been to wait until the patient has invasive disease and then treat this disease with cytotoxic chemotherapy, surgery, or radiation. None of these modalities has been overwhelmingly successful for the treatment of all types of epithelial cancer, in spite of some advances that have occurred.
Accordingly, it has been suggested that an alternative approach to the problem of epithelial cancer is to consider the disease as a process which takes many years to reach its final, invasive stage in man and which might be controlled by physiological or pharmacological mechanisms during its early stages, with the goal of prevention of end-stage, invasive, terminal disease.
Retinoids play an essential role in controlling the normal differentiation of epithelial tissues and are therefore important for controlling premalignant epithelial cell differentiation. It has even been found that retinoids can cause cellular repair of hyperplastic and anaplastic lesions caused by chemical carcinogens. Moreover, retinoid deficiency has been shown, in experimental animals, to enhance susceptibility to chemical carcinogenesis. Indeed, retinoids are essential for the normal cellular differentiation of epithelia that account for more than half of the total primary cancer in both men and women. These epithelia include those of the bronchi and trachea, stomach, intestine, uterus, kidney and bladder, testis, prostate, pancreatic ducts, and skin. In the absence of retinoids in the diet, normal cellular differentiation does not occur in these epithelia.
However, natural retinyl esters, such as retinyl acetate and retinyl palmitate, as well as retinoic acid, have been found to be too toxic at high dosage levels to be of practical value for cancer prevention in higher mammals. Progress has been made recently in identifying synthetic retinoids, for example 13-cis-retinoic acid, that are considerably less toxic than retinoic acid or the natural retinyl esters, and are also more potent in preventing chemical carcinogenesis. See "13-cis-Retinoic Acid:Inhibitor of Bladder Carcinogenesis in the Rat", Science, Feb. 4, 1977, Volume 195, pp 487-489 as well as "13-cis-Retinoic Acid: Inhibition of Bladder Carcinogenesis Induced in Rats by N-Butyl-N-(4-hydroxybutyl) nitrosamine", Science, Nov. 18, 1977, Volume 198, pages 743-744. 13-cis-retinoic acid, however, has not been found to be particularly effective against breast cancer in the rat model discussed hereinafter.
Recent developments in this field, as summarized above, are also discussed in an article entitled "Prevention of Chemical Carcinogenesis by Vitamin A and its Synthetic Analogs (Retinoids)", Federation Proceedings, 35, (May 1, 1976), 1332-1338, in which it is noted that it still remains a goal to find, for practical application to man and other mammals, highly effective synthetic retinoids that also have low toxicity and a high degree of tissue specificity against cancer at any particular organ site. See also the articles in the Fall, 1977, issue of The Southern Research Institute Bulletin (Volume 30, Number 2), pages 3-9 ("CHEMOPREVENTION OF CANCER-Steps Leading to Some Malignancies May Be Reversible" and "How Do Retinoids Work? Studies on Retinoic Acid-Binding Protein"). Other recent publications of interest in this field include "Biological Activity and Metabolism of the Retinoid Axerophthene (Vitamin A Hydrocarbon)", Cancer Research 38, 1734-1738, June 1978; and "Retinoids and Cancer Prevention: The importance of the Terminal Group of the Retinoid Molecule In Modifying Activity and Toxicity" in Carcinogens: Identification and Mechanism of Action, A. C. Griffin & C. R. Shaw, Editors, N.Y. Raven Press, 1978 (in Press).
In prior U.S. patent application Ser. No. 628,177, filed Nov. 3, 1975, now U.S. Pat. No. 4,108,880, N-(4-hydroxyphenyl)-all-trans-retinamide is disclosed as being a good ultraviolet absorber that does not have the irritating effect on skin that would be expected from the use of sunscreening amounts of retinoic acid. This compound is claimed in a divisional of the above-identified application, U.S. patent application Ser. No. 906,168, filed May 15, 1978.
DISCLOSURE OF INVENTION
It has now been found that N-(4-hydroxyphenyl)-all-trans-retinamide, ##STR1##
has an unusually desirable combination of properties-low systemic toxicity, good effectiveness in preventing epithelial cancer in mammals at reasonable dose levels, and adequate target specificity in concentrating at the breast. It is expected that it will also concentrate at one or more other common sites of epithelial cancer such as the bladder, colon, lung and pancreas.
BEST MODE FOR CARRYING OUT THE INVENTION
A suitable method for preparing N-(4-hydroxyphenyl)-all-trans-retinamide is described in Example 1 below.
EXAMPLE 1
A solution of retinoyl chloride was prepared by magnetically stirring 3.00 g. of all-trans-retinoic acid and 0.92 g. of phosphorous trichloride for 2.25 hours in 50 ml. of dry benzene. During 21 minutes, the retinoyl chloride solution was then added to a solution of 5.46 g. of 4-aminophenol in 16 ml. of anhydrous N,N-dimethylformamide and 2 ml. of anhydrous ethyl ether, while stirring under a nitrogen atmosphere and cooling in an ice bath. Stirring was then continued for three hours at room temperature and for an hour more at 50° C.
The reaction mixture was diluted with 150 ml. of ethyl ether. The ether solution was extracted with two 25-ml. portions of cold 5% hydrochloric acid and then was washed with four 25-ml. portions of cold water. After the washed solution was dried over sodium sulfate, the solvent was evaporated, leaving a dark-yellow solid. The solid was recrystallized first from methanol (6 ml. per gram), then from 1:1.7 chloroform-n-hexane (8 ml. per gram). The product had a melting point of 159°-160° C. The proton magnetic resonance spectrum of the product was consistent with the structure with no extraneous resonances.
Anal. Calcd. for C26 H33 NO2 :C, 79.8; H, 8.49; N, 3.58. Found: C, 79.5; H, 8.67; N, 3.56.
In use for the prevention of carcinogenesis, the N-(4-hydroxyphenyl)-all-trans-retinamide is administered systemically, preferably orally, in a pharmaceutically acceptable vehicle compatible therewith at a dosage level effective to prevent or retard carcinogenesis but below that which would be toxic. The drug is administered at regular intervals, conveniently at meal times or once daily. It has been established that the LD50 of the active compound (in Swiss mice) is 436 mg/kg when given interperitoneally and in excess of 400 mg/kg when given orally. On the other hand, oral doses of 32 and 64 mg/kg/day have been found to be very effective in preventing breast cancer in rats. It is believed that for other mammals, a suitable effective dosage level will be within the above range and, probably, lower doses will also prove efficaceous.
EXAMPLE 2
N-(4-hydroxyphenyl)-all-trans-retinamide was compared with retinoic acid in an in vitro screening model for identifying retinoids having activity in preventing carcinogenesis in epithelial tissue. The experimental method, which is described in Experimental Lung Cancer:Intern'l Symp, 575-82, 1974, involves reversal of keratinization in tracheal organ culture.
In brief summary, in the absence of retinoic acid or a synthetic retinoid having similar activity, the test organ culture of tracheal epithelium undergoes abnormal differentiation. Addition of small concentrations of retinoic acid (as low as 10-9 M) will cause reversion to normal tracheal epithelium. Test compounds are compared in activity to retinoic acid or another active standard both as regards squamous metaplasia and keratin production, both of which are measures of abnormal development of the epithelial culture. The results, summarized in Table I below, show that the 4-hydroxyphenyl retinamide is at least as efficacious as retinoic acid at a concentration of 10-8 M, and nearly as efficaceous at 10-9 M, although virtually inefficacious at 10-10 M.
In carrying out the tests reported in Table I, all tracheas were cultured for the first 3 days in medium without retinoid. At this time, some tracheas were collected, while the rest were cultured for a further week in medium containing either no retinoid, or retinoid added at the concentrations shown. These tracheas were collected on the 10th day of culture. Cultures were graded as to the percentage of their total epithelium showing squamous metaplasia on eight cross sections from the middle of each trachea. If more than 40% of the total epithelial length was squamous, it was graded as having severe squamous metaplasia; between 10-40% was graded as marked; between 2-10% was graded as mild; and less than 2% was graded as minimal.
                                  TABLE I                                 
__________________________________________________________________________
Reversal of Keratinized Squamous Metaplastic Lesions of Vitamin A         
Deficiency                                                                
in Tracheal Organ Cultures Treated with Retinoids                         
                                      % of Cultures with                  
                 % of Cultures with Respective Amounts                    
                                      Keratin and                         
Treatment of Cultures                                                     
                 of Squamous Metaplasia                                   
                                      Keratohyaline                       
(number of cultures)                                                      
                 None                                                     
                     Minimal                                              
                          Mild                                            
                             Marked                                       
                                  Severe                                  
                                      Granules                            
__________________________________________________________________________
No Retinoid,                                                              
collected day 3                                                           
              (152)                                                       
                 12   8   42 26   79  71                                  
No Retinoid,                                                              
collected day 10                                                          
              (140)                                                       
                  1   2   11 50   34  95                                  
Retinoic Acid                                                             
10.sup.-8 M   (26)                                                        
                 27  49   23  0    0   0                                  
10.sup.-9 M   (134)                                                       
                 16  37   32 12    2   3                                  
10.sup.-10 M  (47)                                                        
                  9   4   43 17   28  32                                  
4-Hydroxyphenyl Retinamide                                                
10.sup.-8 M   (10)                                                        
                 20  80    0  0    0   0                                  
10.sup.-9 M   (10)                                                        
                 20  20   30  0   30  40                                  
10.sup.-10 M  (8)                                                         
                  0   0   12 75   12  100                                 
__________________________________________________________________________
EXAMPLE 3
On the basis of the encouraging results summarized in the foregoing example, N-(4-hydroxyphenyl)-all-trans-retinamide was compared to retinyl acetate in the experimental assay for efficacy against rat breast cancer described in Nature Vol. 267, pp 620-621 (June 16, 1977), which measures the ability to inhibit mammary carcinogenesis induced by N-methyl-N-nitrosourea (MNU). The test conditions and results after 10 1/2 weeks of testing are set forth in Table II. The results of further extension of the tests, comparing the 4-hydroxyphenyl retinamide only to placebo, after 18 weeks with high dose MNU and 21 weeks with low dose MNU, are set forth in Table III. The results using these two different levels of MNU and two dietary levels of retinoid are shown graphically in FIGS. 1 and 2 after 18 weeks of testing.
Not only is the 4-hydroxyphenyl retinamide substantially as efficacious as retinyl acetate, it is also less toxic. Of particular importance is the fact that, unlike the natural retinyl esters, this retinamide does not accumulate in the liver in appreciable amounts, thus avoiding the hepatotoxicity associated with prolonged use of the natural esters.
                                  TABLE II                                
__________________________________________________________________________
Relative Effects of Retinyl Acetate and 4-Hydroxyphenyl Retinamide        
On N-Methyl-N-Nitrosourea (MNU) - Induced Mammary Cancer (73 days)        
                                  Mammary Tumor                           
Carcinogen  Retinoid              Incidence                               
__________________________________________________________________________
Saline      Placebo               0/10   (0%)                             
Saline      Retinyl Acetate, 328 mg/kg diet                               
                                  0/10   (0%)                             
Saline      Retinyl Acetate, 656 mg/kg diet                               
                                  0/10   (0%)                             
Saline      4-Hydroxyphenyl Retinamide, 391 mg/kg diet                    
                                  0/10   (0%)                             
Saline      4-hydroxyphenyl Retinamide, 782 mg/kg diet                    
                                  0/10   (0%)                             
MNU, high dose                                                            
            Placebo               14/17  (82%)                            
MNU, high dose                                                            
            Retinyl Acetate, 328 mg/kg diet                               
                                  5/19   (26%)                            
MNU, high dose                                                            
            Retinyl Acetate, 656 mg/kg diet                               
                                  4/17   (24%)                            
MNU, high dose                                                            
            4-Hydroxyphenyl Retinamide, 391 mg/kg diet                    
                                  5/16   (31%)                            
MNU, high dose                                                            
            4-Hydroxyphenyl Retinamide, 782 mg/kg diet                    
                                  0/17   (0%)                             
MNU, low dose                                                             
            Placebo               1/40   (2.5%)                           
MNU, low dose                                                             
            Retinyl Acetate, 328 mg/kg diet                               
                                  0/39   (0%)                             
MNU, low dose                                                             
            Retinyl Acetate, 656 mg/kg diet                               
                                  0/40   (0%)                             
MNU, low dose                                                             
            4-Hydroxyphenyl Retinamide, 391 mg/kg diet                    
                                  0/40   (0%)                             
MNU, low dose                                                             
            4-Hydroxyphenyl Retinamide, 782 mg/kg diet                    
                                  0/39   (0%)                             
__________________________________________________________________________
Animals: Female Sprague-Dawley rats obtained from ARS Sprague-Dawley.     
Carcinogen:                                                               
         Crystalline MNU. Rats received 2 I.V. injections at 50 and 57    
         days of age.                                                     
         High dose is 50 mg/kg; low dose 15 mg/kg.                        
Retinoids:                                                                
         Retinoids were dissolved in solvent and blended into the diets.  
         Rats were                                                        
         placed on diets 3 days after last MNU injection.                 
Retinoid Solvent:                                                         
         50 gm trioctanoin:ethanol (3:1), 0.05 ml Tenox 20, 0.05 ml       
         DL-α-Tocopherol/kg                                         
         Wayne lab meal.                                                  
Retinoid Placebo:                                                         
         50 gm retinoid solvent/kg diet.                                  
__________________________________________________________________________

                                  TABLE III                               
__________________________________________________________________________
Effect of 4-Hydroxyphenyl Retinamide on N-Methyl-N-Nitrosourea            
(MNU) - Induced Mammary Cancer                                            
                               Mammary Tumor                              
                                        Total Number                      
Carcinogen                                                                
         Retinoid              Incidence                                  
                                        of Tumors                         
__________________________________________________________________________
Saline   Placebo               0/10 (0%)                                  
                                        0                                 
Saline   4-Hydroxyphenyl Retinamide, 391 mg/kg diet                       
                               0/10 (0%)                                  
                                        0                                 
Saline   4-Hydroxyphenyl Retinamide, 782 mg/kg diet                       
                               0/10 (0%)                                  
                                        0                                 
MNU, high dose                                                            
         Placebo               17/17                                      
                                    (100%)                                
                                        85                                
MNU, high dose                                                            
         4-Hydroxyphenyl Retinamide, 391 mg/kg diet                       
                               13/16                                      
                                    (81%)                                 
                                        48                                
MNU, high dose                                                            
         4-Hydroxyphenyl Retinamide, 782 mg/kg diet                       
                               11/17                                      
                                    (64%)                                 
                                        37                                
MNU, low dose                                                             
         Placebo               12/40                                      
                                    (30%)                                 
                                        13                                
MNU, low dose                                                             
         4-Hydroxyphenyl Retinamide, 391 mg/kg diet                       
                               5/40 (12%)                                 
                                        5                                 
MNU, low dose                                                             
         4-Hydroxyphenyl Retinamide, 782 mg/kg diet                       
                               3/39 (8%)                                  
                                        4                                 
__________________________________________________________________________
Animals: Female Sprague-Dawley rats obtained from ARS Sprague-Dawley.     
Carcinogen:                                                               
         Crystalline MNU. Rats received 2 I.V. injections at 50 and 57    
         days of age.                                                     
         High dose is 50 mg/kg; low dose 15 mg/kg. Rats on high dose of   
         MNU were                                                         
         sacrificed after 18 weeks.                                       
Retinoids:                                                                
         Retinoids were dissolved in solvent and blended into the diets.  
         Rats were                                                        
         placed on diets 3 days after last MNU injection.                 
Retinoid Solvent:                                                         
         50 gm trioctanoin:ethanol (3:1), 0.05 ml Tenox 20, 0.05 ml       
         DL-α-Tocopherol/kg                                         
         Wayne lab meal.                                                  
Placebo: 50 gm retinoid solvent/kg diet.                                  
__________________________________________________________________________
Variations can, of course, be made without departing from the spirit and scope of the invention.

Claims (10)

What is claimed is:
1. A method of treating carcinogenesis in epithelial tissue in a mammal in need of said treatment, which comprises periodically administering to the subject mammal an effective amount for treating carcinogenesis of N-(4-hydroxyphenyl)-all-trans-retinamide.
2. The method of claim 1 wherein said hydroxyphenyl retinamide is administered orally.
3. The method of claim 2 wherein said hydroxyphenyl retinamide is administered at least once daily.
4. The method of claim 3 wherein said hydroxyphenyl retinamide is administered in an amount up to about 65 mg/kg/day.
5. The method of claim 4 wherein said amount does not exceed about 35 mg/kg/day.
6. The method of claim 1 wherein said hydroxyphenyl retinamide is administered in an amount up to about 65 mg/kg/day.
7. The method of claim 6 wherein said amount does not exceed about 35 mg/kg/day.
8. The method of claim 1 wherein said epithelial tissue is breast tissue.
9. A composition for treating carcinogenesis in epithelial tissue comprising an effective amount for treating carcinogenesis of N-(4-hydroxyphenyl)-all-trans-retinamide in a pharmaceutically acceptable systemic vehicle compatible therewith.
10. The composition of claim 9 in oral dosage form.
US05/929,094 1978-07-31 1978-07-31 Method of treating carcinogenesis Expired - Lifetime US4323581A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US05/929,094 US4323581A (en) 1978-07-31 1978-07-31 Method of treating carcinogenesis
ZA786950A ZA786950B (en) 1978-07-31 1978-12-12 Method of preventing carcinogenesis
CA000329784A CA1142092A (en) 1978-07-31 1979-06-14 Method of preventing carcinogenesis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/929,094 US4323581A (en) 1978-07-31 1978-07-31 Method of treating carcinogenesis

Publications (1)

Publication Number Publication Date
US4323581A true US4323581A (en) 1982-04-06

Family

ID=25457315

Family Applications (1)

Application Number Title Priority Date Filing Date
US05/929,094 Expired - Lifetime US4323581A (en) 1978-07-31 1978-07-31 Method of treating carcinogenesis

Country Status (3)

Country Link
US (1) US4323581A (en)
CA (1) CA1142092A (en)
ZA (1) ZA786950B (en)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3610531A1 (en) * 1985-03-28 1986-10-16 Mcneilab, Inc., Springhouse, Pa. MEDICINAL PRODUCTS WITH A N- (4-HYDROXYPHENYL) -RETINAMIDE CONTENT WITH INCREASED BIOAVAILABILITY
US4743400A (en) * 1986-09-22 1988-05-10 Mcneilab, Inc. Process for preparing retinoyl chlorides
AU682878B2 (en) * 1993-07-20 1997-10-23 Ortho Pharmaceutical Corporation Process for the preparation of (N)-(4-hydroxyphenyl)-retinamide
US5703130A (en) * 1995-06-07 1997-12-30 Institute Of Materia Medica, An Institute Of The Chinese Academy Of Medical Sciences Chalcone retinoids and methods of use of same
US5716982A (en) * 1995-06-07 1998-02-10 Institute Of Materia Medica, An Institute Of The Chinese Academy Of Medical Sciences Retinoids and methods of use of same
US5968940A (en) * 1995-06-08 1999-10-19 Institute Of Materia Medica Retinoids and methods of use of same
US6352844B1 (en) 1998-06-29 2002-03-05 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
US6368831B1 (en) 1998-06-29 2002-04-09 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
US20030153740A1 (en) * 1987-12-16 2003-08-14 Institut Pasteur Novel steroid/thyroid hormone receptor-related gene, which is inappropriately expressed in human heptocellular carcinoma, and which is a retinoic acid receptor
US20060094063A1 (en) * 2004-11-04 2006-05-04 Sytera, Inc. Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation
US20060099714A1 (en) * 2004-10-25 2006-05-11 Sytera, Inc. Detection and analysis of ophthalmically-relevant fluorescent molecules
US20060167088A1 (en) * 2004-06-23 2006-07-27 Sytera, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
US20070015827A1 (en) * 2005-07-11 2007-01-18 Sytera, Inc. Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation
US7169819B2 (en) 2000-12-05 2007-01-30 Childrens Hospital Los Angeles Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same
WO2007084786A1 (en) 2006-01-20 2007-07-26 Novartis Ag Pyrimidine derivatives used as pi-3 kinase inhibitors
US20070258970A1 (en) * 2003-12-09 2007-11-08 Robert Blumenthal Methods for Inhibiting Hiv and Other Viral Infections by Modulating Ceramide Metabolism
US7321064B1 (en) 2007-03-08 2008-01-22 Cedarburg Pharmaceuticals, Inc. Preparation of amides of retinoic acid via mixed anhydride and mixed carbonate intermediates
US20080153907A1 (en) * 2005-02-25 2008-06-26 Nanohybrid Co., Ltd. Pharmaceutical Composition for the Treatment of Cancer Comprising Lhm-Ra Complex
WO2009080694A1 (en) 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as pi 3 kinase inhibitors
US20100048561A1 (en) * 2006-04-06 2010-02-25 Novartis Vaccines & Diagnostics, Inc. Quinazolines for pdk1 inhibition
US20100075965A1 (en) * 2006-02-14 2010-03-25 Novartis Ag Pi3 kinase inhibitors and methods of their use
CN101229147B (en) * 2007-12-24 2010-09-01 复旦大学 Use of N-4-hydroxyphenyl retinamide on preparing anti-hepatic fibrosis medicine
EP2266590A2 (en) 2002-02-22 2010-12-29 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
WO2011000905A1 (en) 2009-07-02 2011-01-06 Novartis Ag Substituted 2-carboxamide cycloamino ureas
EP2277595A2 (en) 2004-06-24 2011-01-26 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
WO2012016970A1 (en) 2010-08-02 2012-02-09 Novartis Ag A crystalline form of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4 -methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide and its use as pi3k inhibitor
WO2012104776A1 (en) 2011-01-31 2012-08-09 Novartis Ag Novel heterocyclic derivatives
WO2013061305A1 (en) 2011-10-28 2013-05-02 Novartis Ag Novel purine derivatives and their use in the treatment of disease
WO2013173283A1 (en) 2012-05-16 2013-11-21 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
US8709379B2 (en) 2006-03-29 2014-04-29 Scitech Development, Llc Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
WO2017077445A1 (en) 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
EP4000619A1 (en) 2013-12-06 2022-05-25 Novartis AG Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108880A (en) * 1975-11-03 1978-08-22 Johnson & Johnson Esters of retinoic acid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108880A (en) * 1975-11-03 1978-08-22 Johnson & Johnson Esters of retinoic acid

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3610531A1 (en) * 1985-03-28 1986-10-16 Mcneilab, Inc., Springhouse, Pa. MEDICINAL PRODUCTS WITH A N- (4-HYDROXYPHENYL) -RETINAMIDE CONTENT WITH INCREASED BIOAVAILABILITY
US4665098A (en) * 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
US4743400A (en) * 1986-09-22 1988-05-10 Mcneilab, Inc. Process for preparing retinoyl chlorides
US20030153740A1 (en) * 1987-12-16 2003-08-14 Institut Pasteur Novel steroid/thyroid hormone receptor-related gene, which is inappropriately expressed in human heptocellular carcinoma, and which is a retinoic acid receptor
AU682878B2 (en) * 1993-07-20 1997-10-23 Ortho Pharmaceutical Corporation Process for the preparation of (N)-(4-hydroxyphenyl)-retinamide
US5703130A (en) * 1995-06-07 1997-12-30 Institute Of Materia Medica, An Institute Of The Chinese Academy Of Medical Sciences Chalcone retinoids and methods of use of same
US5716982A (en) * 1995-06-07 1998-02-10 Institute Of Materia Medica, An Institute Of The Chinese Academy Of Medical Sciences Retinoids and methods of use of same
US5968940A (en) * 1995-06-08 1999-10-19 Institute Of Materia Medica Retinoids and methods of use of same
US6352844B1 (en) 1998-06-29 2002-03-05 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
US6368831B1 (en) 1998-06-29 2002-04-09 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
US7169819B2 (en) 2000-12-05 2007-01-30 Childrens Hospital Los Angeles Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
EP2266590A2 (en) 2002-02-22 2010-12-29 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
US20070258970A1 (en) * 2003-12-09 2007-11-08 Robert Blumenthal Methods for Inhibiting Hiv and Other Viral Infections by Modulating Ceramide Metabolism
US20060167088A1 (en) * 2004-06-23 2006-07-27 Sytera, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
US8314152B2 (en) 2004-06-23 2012-11-20 Acucela, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
US8410168B2 (en) 2004-06-23 2013-04-02 Acucela, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
EP2025336A1 (en) 2004-06-23 2009-02-18 Sirion Therapeutics, Inc. Retinyl derivatives for treating ophtalmic conditions
EP2277516A1 (en) 2004-06-23 2011-01-26 ReVision Therapeutics, Inc. Retinyl derivatives for treating ophtalmic conditions
EP2277595A2 (en) 2004-06-24 2011-01-26 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
US20060099714A1 (en) * 2004-10-25 2006-05-11 Sytera, Inc. Detection and analysis of ophthalmically-relevant fluorescent molecules
US20060094063A1 (en) * 2004-11-04 2006-05-04 Sytera, Inc. Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation
US7432307B2 (en) 2004-11-04 2008-10-07 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation
US20080153907A1 (en) * 2005-02-25 2008-06-26 Nanohybrid Co., Ltd. Pharmaceutical Composition for the Treatment of Cancer Comprising Lhm-Ra Complex
US20070015827A1 (en) * 2005-07-11 2007-01-18 Sytera, Inc. Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation
WO2007084786A1 (en) 2006-01-20 2007-07-26 Novartis Ag Pyrimidine derivatives used as pi-3 kinase inhibitors
EP2261223A1 (en) 2006-01-20 2010-12-15 Novartis AG Pyrimidine derivatives used as pi-3 kinase inhibitors
US20100075965A1 (en) * 2006-02-14 2010-03-25 Novartis Ag Pi3 kinase inhibitors and methods of their use
US8709379B2 (en) 2006-03-29 2014-04-29 Scitech Development, Llc Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
US20100048561A1 (en) * 2006-04-06 2010-02-25 Novartis Vaccines & Diagnostics, Inc. Quinazolines for pdk1 inhibition
US7932262B2 (en) 2006-04-06 2011-04-26 Novartis Ag Quinazolines for PDK1 inhibition
US20080221349A1 (en) * 2007-03-08 2008-09-11 Cabaj John E Preparation of Amides of Retinoic Acid Via Mixed Anhydride and Mixed Carbonate Intermediates
US7321064B1 (en) 2007-03-08 2008-01-22 Cedarburg Pharmaceuticals, Inc. Preparation of amides of retinoic acid via mixed anhydride and mixed carbonate intermediates
WO2009080694A1 (en) 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as pi 3 kinase inhibitors
CN101229147B (en) * 2007-12-24 2010-09-01 复旦大学 Use of N-4-hydroxyphenyl retinamide on preparing anti-hepatic fibrosis medicine
WO2011000905A1 (en) 2009-07-02 2011-01-06 Novartis Ag Substituted 2-carboxamide cycloamino ureas
WO2012016970A1 (en) 2010-08-02 2012-02-09 Novartis Ag A crystalline form of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4 -methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl)-amide and its use as pi3k inhibitor
WO2012104776A1 (en) 2011-01-31 2012-08-09 Novartis Ag Novel heterocyclic derivatives
WO2013061305A1 (en) 2011-10-28 2013-05-02 Novartis Ag Novel purine derivatives and their use in the treatment of disease
WO2013173283A1 (en) 2012-05-16 2013-11-21 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
EP4000619A1 (en) 2013-12-06 2022-05-25 Novartis AG Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
WO2017077445A1 (en) 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib

Also Published As

Publication number Publication date
CA1142092A (en) 1983-03-01
ZA786950B (en) 1980-08-27

Similar Documents

Publication Publication Date Title
US4323581A (en) Method of treating carcinogenesis
US4310546A (en) Novel retinoids and their use in preventing carcinogenesis
AU667864B2 (en) Pharmaceutical compositions
US5736576A (en) Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
JPH08504408A (en) 5-Methanesulfonamide-1-indanone as a cyclooxygenase-2 inhibitor
JP2023520668A (en) Nanoparticles containing drug dimers and uses thereof
KR100201749B1 (en) Pharmaceutical compositions containing diphenyl compounds which inhibit arachidonic acid metabolism
Swanson et al. Biotransformation and biological activity of N-(4-hydroxyphenyl) retinamide derivatives in rodents.
JPS62145019A (en) Anti-inflammatory agent
US5552389A (en) Suppressory compositions against hepatic metastases of tumors
Thompson et al. Inhibition of urinary bladder cancer by N-(ethyl)-all-trans-retinamide and N-(2-hydroxyethyl)-all-trans-retinamide in rats and mice
CA1137873A (en) Composition of treatment of hyperpigmentary dermatoses and the like
US4194007A (en) α-Hydroxyretinoic acid, α-ketoretinoic acid and mixtures and their use in treating skin conditions
BR9814053B1 (en) lipophilic diesters of chelating agents.
WO2018086241A1 (en) Ph-sensitive 1,4-disubstituted zinc phthalocyanine coordination complex, preparation method therefore, and application thereof in medicine
JPH06507390A (en) Use of cucurbitin for the preparation of cosmetic or especially dermatological pharmaceutical antiallergic compositions and methods involving its application
EP0650473B1 (en) Radioimaging and radiochemotherapy phenolic thioether amines and acyl derivatives thereof for use in diagnosing and treating pigmentation disorders
CN116444408B (en) A multi-target disulfiram derivative, pharmaceutical composition and its anti-tumor application
JPH0368515A (en) Antiallergic drug
EP3756660B1 (en) Medicament having anti-inflammatory bowel disease function, and preparation method therefor and application thereof
EP0755917A1 (en) N,N'-di(aralkyl) N,N'-di(carboxyalkyl) alkylen- di- or triamino-derivatives and N-(aralkyl) N'-(carboxyalkyl) N,N'-di (carboxyalkyl) alkylen- di- or triamino-derivatives and their use in pharmacy and cosmetics
EP0606614B1 (en) Nonatetraenoic acid derivative
Lambelin et al. Carcinogenicity of 6-aminochrysene in mice
US4863969A (en) Treatment of premalignant lesions and certain malignant tumors
JP4008534B2 (en) Acne treatment

Legal Events

Date Code Title Description
AS Assignment

Owner name: JOHNSON & JOHNSON, A CORP. OF NJ.

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:GANDER, ROBERT J.;REEL/FRAME:003938/0287

Effective date: 19780728

STCF Information on status: patent grant

Free format text: PATENTED CASE